Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide
In Vivo · 2025
DOI: 10.21873/invivo.14016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift In Vivo, 2025. Verfasst von Yujiro Nagata und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; yujiro-nagata@med.uoeh-u.ac.jp. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Prostate-Specific Antigen, Androgen Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; yujiro-nagata@med.uoeh-u.ac.jp.
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Urology, Wakamatsu Hospital of University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Urology, Local Incorporated Administrative Agency Kurate Hospital, Kurate, Japan.
Zitieren
APA
Nagata, Y., Sugi, T., Yamamura, S., Sugita, Y., Mizushima, Y., Matsukawa, T., Takaba, T., Jojima, K., Higashijima, K., Matsumoto, M., Minato, A., Tomisaki, I., Kashiwagi, E., & Fujimoto, N. (2025). Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide. In Vivo. https://doi.org/10.21873/invivo.14016
Vancouver
Nagata Y, Sugi T, Yamamura S, Sugita Y, Mizushima Y, Matsukawa T, et al. Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide. In Vivo. 2025. doi:10.21873/invivo.14016
BibTeX
@article{Nagata2025,
author = {Nagata, Yujiro and Sugi, Takaomi and Yamamura, Sohei and Sugita, Yoshihiro and Mizushima, Yui and Matsukawa, Takuo and Takaba, Tomohisa and Jojima, Kazumasa and Higashijima, Katsuyoshi and Matsumoto, Masahiro and Minato, Akinori and Tomisaki, Ikko and Kashiwagi, Eiji and Fujimoto, Naohiro},
title = {Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14016}
}
EUVIMED